{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:57Z","timestamp":1792037097422,"version":"4.4.0"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"DOI":"10.13039\/100000062","name":"National Institutes of Health\/National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK111693"],"award-info":[{"award-number":["R01DK111693"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institutes of Health\/National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK122212"],"award-info":[{"award-number":["R01DK122212"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This study describes a novel drug treatment to prevent vascular calcification in patients with CKD and on dialysis.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>For the first time, we describe a potential therapeutic to treat renal osteodystrophy and vascular calcification in CKD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This study describes a novel therapeutic to prevent and possibly to treat calciphylaxis in patients with CKD and on dialysis.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abnormalities in calcium, phosphorus, PTH, vitamin D metabolism, bone, and vascular calcification occur in chronic kidney disease mineral bone disorder (CKD-MBD). Calciphylaxis, involving painful, ulcerative skin lesions, is also a major problem associated with CKD-MBD. There are no quality medical interventions to address these clinical issues. Bone ASARM peptides are strong inhibitors of mineralization and induce hypophosphatemia by inhibiting phosphate uptake from the gut. We hypothesize treatment of CKD-MBD rats with ASARM peptides will reverse hyperphosphatemia, reduce soft-tissue calcification, and prevent calciphylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To test our hypothesis, we assessed the effects of synthetic ASARM peptide in rats that had undergone a subtotal 5\/6th nephrectomy (56NEPHREX), a rodent model of CKD-MBD. All rats were fed a high phosphate diet (2% Pi) to worsen mineral metabolism defects. Changes in serum potassium, phosphate, BUN, creatinine, PTH, FGF23, and calcium were assessed in response to 28 days of ASARM peptide infusion. Also, changes in bone quality, soft-tissue calcification, and expression of gut Npt2b (Slc34a2) were studied following ASARM peptide treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rats that had undergone 56NEPHREX treated with ASARM peptide showed major improvements in hyperphosphatemia, blood urea nitrogen (BUN), and bone quality compared with vehicle controls. Also, ASARM-infused 56NEPHREX rats displayed improved renal, brain, and cardiovascular calcification. Notably, ASARM peptide infusion prevented the genesis of subdermal medial blood vessel calcification and calciphylaxis-like lesions in 56NEPHREX rats compared with vehicle controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ASARM peptide infusion corrects hyperphosphatemia and improves vascular calcification, renal calcification, brain calcification, bone quality, renal function, and skin mineralization abnormalities in 56NEPHREX rats. These findings confirm our hypothesis and support the utility of ASARM peptide treatment in patients with CKD-MBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0002782022","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T14:14:42Z","timestamp":1661868882000},"page":"1683-1698","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Correction of Vascular Calcification and Hyperphosphatemia in CKD Rats Treated with ASARM Peptide"],"prefix":"10.34067","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9809-3660","authenticated-orcid":false,"given":"Peter S.","family":"Rowe","sequence":"first","affiliation":[{"name":"The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1776-2533","authenticated-orcid":false,"given":"Alan L.","family":"Yu","sequence":"additional","affiliation":[{"name":"The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-5745","authenticated-orcid":false,"given":"Jason R.","family":"Stubbs","sequence":"additional","affiliation":[{"name":"The Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"B3-20250825","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1523-1755.2004.00894.x","article-title":"The burden of Kidney Disease: Improving Global Outcomes","volume":"66","author":"Eknoyan","year":"2004","journal-title":"Kidney Int"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 annual data report: Epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","article-title":"Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization","volume":"164","author":"Keith","year":"2004","journal-title":"Arch Intern Med"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(12)61272-0","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-analysis","volume":"380","author":"Mahmoodi","year":"2012","journal-title":"Lancet"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5414\/CN108940","article-title":"Coronary artery calcification in CKD-5D patients is tied to adverse cardiac function and increased mortality","volume":"86","author":"Anaya","year":"2016","journal-title":"Clin Nephrol"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamacardio.2017.0363","article-title":"Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease","volume":"2","author":"Chen","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfi236","article-title":"Vascular calcification and cardiovascular function in chronic kidney disease","volume":"21","author":"Sigrist","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.3390\/ijms23137362","article-title":"Phosphate in the context of cognitive impairment and other neurological disorders occurrence in chronic kidney disease","volume":"23","author":"Rroji","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fcvm.2020.00096","article-title":"Cerebrovascular disease and cognition in chronic kidney disease patients","volume":"7","author":"Miglinas","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11914-018-0486-0","article-title":"CKD-MBD: From the pathogenesis to the identification and development of potential novel therapeutic targets","volume":"16","author":"Elias","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/heartjnl-2011-300570","article-title":"Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: A cardiac magnetic resonance study","volume":"98","author":"Chue","year":"2012","journal-title":"Heart"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1681\/ASN.2007070760","article-title":"The mechanism of phosphorus as a cardiovascular risk factor in CKD","volume":"19","author":"Mathew","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00774-005-0668-6","article-title":"Vascular calcification in chronic kidney disease","volume":"24","author":"Jono","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium\u00d7phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1681\/ASN.2021101327","article-title":"Interventions to attenuate vascular calcification progression in chronic kidney disease: A systematic review of clinical trials","volume":"33","author":"Xu","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B23-20250825","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.108.783738","article-title":"Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis","volume":"118","author":"Shroff","year":"2008","journal-title":"Circulation"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/sdi.12710","article-title":"Current and potential therapeutic strategies for the management of vascular calcification in patients with chronic kidney disease including those on dialysis","volume":"31","author":"Ruderman","year":"2018","journal-title":"Semin Dial"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/geno.2000.6235","article-title":"MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia","volume":"67","author":"Rowe","year":"2000","journal-title":"Genomics"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2015.05.030","article-title":"Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif","volume":"79","author":"Zelenchuk","year":"2015","journal-title":"Bone"},{"key":"B27-20250825","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bone.2014.11.011","article-title":"SPR4-peptide alters bone metabolism of normal and HYP mice","volume":"72","author":"Zelenchuk","year":"2015","journal-title":"Bone"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"e97326","DOI":"10.1371\/journal.pone.0097326","article-title":"PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism","volume":"9","author":"Zelenchuk","year":"2014","journal-title":"PLoS One"},{"key":"B29-20250825","doi-asserted-by":"crossref","first-page":"e56749","DOI":"10.1371\/journal.pone.0056749","article-title":"MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia","volume":"8","author":"Salmon","year":"2013","journal-title":"PLoS One"},{"key":"B30-20250825","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bone.2012.06.022","article-title":"MEPE is a novel regulator of growth plate cartilage mineralization","volume":"51","author":"Staines","year":"2012","journal-title":"Bone"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bone.2012.01.010","article-title":"Tooth dentin defects reflect genetic disorders affecting bone mineralization","volume":"50","author":"Opsahl Vital","year":"2012","journal-title":"Bone"},{"key":"B32-20250825","doi-asserted-by":"crossref","first-page":"F783","DOI":"10.1152\/ajprenal.00304.2010","article-title":"ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate","volume":"300","author":"David","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B33-20250825","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jbmr.345","article-title":"Sclerostin is a locally acting regulator of late-osteoblast\/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism","volume":"26","author":"Atkins","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B34-20250825","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2353\/ajpath.2010.091231","article-title":"Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin","volume":"177","author":"Boukpessi","year":"2010","journal-title":"Am J Pathol"},{"key":"B35-20250825","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00223-009-9313-z","article-title":"MEPE\u2019s diverse effects on mineralization","volume":"86","author":"Boskey","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"B36-20250825","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000151382","article-title":"Dentin noncollagenous matrix proteins in familial hypophosphatemic rickets","volume":"189","author":"Gaucher","year":"2009","journal-title":"Cells Tissues Organs"},{"key":"B37-20250825","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1210\/en.2009-0216","article-title":"Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator","volume":"150","author":"David","year":"2009","journal-title":"Endocrinology"},{"key":"B38-20250825","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1210\/en.2007-1205","article-title":"Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP","volume":"149","author":"Martin","year":"2008","journal-title":"Endocrinology"},{"key":"B39-20250825","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1677\/joe.1.07059","article-title":"Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity","volume":"192","author":"Rowe","year":"2007","journal-title":"J Endocrinol"},{"key":"B40-20250825","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bone.2006.04.012","article-title":"Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin","volume":"39","author":"Rowe","year":"2006","journal-title":"Bone"},{"key":"B41-20250825","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bone.2004.09.015","article-title":"Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: A model for impaired mineralization in X-linked rickets (HYP)","volume":"36","author":"Rowe","year":"2005","journal-title":"Bone"},{"key":"B42-20250825","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.bone.2003.10.005","article-title":"MEPE has the properties of an osteoblastic phosphatonin and minhibin","volume":"34","author":"Rowe","year":"2004","journal-title":"Bone"},{"key":"B43-20250825","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1677\/joe.1.05989","article-title":"Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): Implications for phosphaturia and rickets","volume":"183","author":"Bresler","year":"2004","journal-title":"J Endocrinol"},{"key":"B44-20250825","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/ndt\/gfq263","article-title":"Direct micropuncture evidence that matrix extracellular phosphoglycoprotein inhibits proximal tubular phosphate reabsorption","volume":"25","author":"Shirley","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"B45-20250825","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1681\/ASN.2008030315","article-title":"Matrix extracellular phosphoglycoprotein inhibits phosphate transport","volume":"19","author":"Marks","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B46-20250825","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ndt\/gfm535","article-title":"Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption","volume":"23","author":"Dobbie","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B47-20250825","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1359\/jbmr.090832","article-title":"Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage","volume":"25","author":"Addison","year":"2010","journal-title":"J Bone Miner Res"},{"key":"B48-20250825","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1359\/jbmr.080601","article-title":"MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: An inhibition regulated by PHEX cleavage of ASARM","volume":"23","author":"Addison","year":"2008","journal-title":"J Bone Miner Res"},{"key":"B49-20250825","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1523-1755.2001.00772.x","article-title":"Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals","volume":"60","author":"Hoyer","year":"2001","journal-title":"Kidney Int"},{"key":"B50-20250825","doi-asserted-by":"crossref","first-page":"F764","DOI":"10.1152\/ajprenal.00201.2015","article-title":"Do ASARM peptides play a role in nephrogenic systemic fibrosis?","volume":"309","author":"Rowe","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B52-20250825","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jbmr.516","article-title":"Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease","volume":"27","author":"Stubbs","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B53-20250825","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1681\/ASN.V4122023","article-title":"Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury","volume":"4","author":"Griffin","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"B54-20250825","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/nep.12279","article-title":"A practical guide to subtotal nephrectomy in the rat with subsequent methodology for assessing renal and cardiac function","volume":"19","author":"Zhang","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"B55-20250825","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-nutr-071816-064607","article-title":"Dietary phosphorus intake and the kidney","volume":"37","author":"Chang","year":"2017","journal-title":"Annu Rev Nutr"},{"key":"B56-20250825","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12937-015-0017-0","article-title":"Association between phosphorus intake and bone health in the NHANES population","volume":"14","author":"Lee","year":"2015","journal-title":"Nutr J"},{"key":"B57-20250825","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3945\/ajcn.112.053934","article-title":"Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population","volume":"98","author":"Calvo","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"B58-20250825","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/ATVBAHA.109.196675","article-title":"Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community","volume":"30","author":"Larsson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B61-20250825","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1210\/jc.2003-032031","article-title":"Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density","volume":"89","author":"Jain","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B62-20250825","first-page":"722","article-title":"Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia","volume":"118","author":"Yuan","year":"2008","journal-title":"J Clin Invest"},{"key":"B63-20250825","doi-asserted-by":"crossref","first-page":"e973","DOI":"10.1259\/bjr\/13040401","article-title":"Ex vivo imaging of mouse brain using micro-CT with non-ionic iodinated contrast agent: A comparison with myelin staining","volume":"85","author":"Saito","year":"2012","journal-title":"Br J Radiol"},{"key":"B64-20250825","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.kint.2018.03.016","article-title":"Questionable specificity of histologic findings in calcific uremic arteriolopathy","volume":"94","author":"Ellis","year":"2018","journal-title":"Kidney Int"},{"key":"B65-20250825","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1681\/ASN.2015091065","article-title":"A nationally representative study of calcific uremic arteriolopathy risk factors","volume":"27","author":"Nigwekar","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B66-20250825","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaad.2006.08.065","article-title":"Calciphylaxis: Natural history, risk factor analysis, and outcome","volume":"56","author":"Weenig","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B67-20250825","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2215\/CJN.00530108","article-title":"Calciphylaxis from nonuremic causes: A systematic review","volume":"3","author":"Nigwekar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B68-20250825","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cvr\/cvm049","article-title":"Nitric oxide regulates vascular calcification by interfering with TGF- signalling","volume":"77","author":"Kanno","year":"2008","journal-title":"Cardiovasc Res"},{"key":"B69-20250825","doi-asserted-by":"crossref","first-page":"F1060","DOI":"10.1152\/ajprenal.00191.2002","article-title":"Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models","volume":"285","author":"Zeisberg","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"B70-20250825","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jbmr.3894","article-title":"Kidney disease progression does not decrease intestinal phosphorus absorption in a rat model of chronic kidney disease-mineral bone disorder","volume":"35","author":"Vorland","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B71-20250825","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/sj.ki.5002292","article-title":"Intestinal phosphate absorption in a model of chronic renal failure","volume":"72","author":"Marks","year":"2007","journal-title":"Kidney Int"},{"key":"B72-20250825","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2011121213","article-title":"Npt2b deletion attenuates hyperphosphatemia associated with CKD","volume":"23","author":"Schiavi","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B73-20250825","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1681\/ASN.2008030315","article-title":"Matrix extracellular phosphoglycoprotein inhibits phosphate transport","volume":"19","author":"Marks","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B74-20250825","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41413-019-0051-1","article-title":"DMP1 prevents osteocyte alterations, FGF23 elevation and left ventricular hypertrophy in mice with chronic kidney disease","volume":"7","author":"Dussold","year":"2019","journal-title":"Bone Res"},{"key":"B75-20250825","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.kint.2016.12.029","article-title":"The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease","volume":"91","author":"Graciolli","year":"2017","journal-title":"Kidney Int"},{"key":"B76-20250825","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i1.50","article-title":"Regulation of bone-renal mineral and energy metabolism: The PHEX, FGF23, DMP1, MEPE ASARM pathway","volume":"22","author":"Rowe","year":"2012","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B77-20250825","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/bj20030287","article-title":"Human recombinant endopeptidase PHEX has a strict S1\u2032 specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein","volume":"373","author":"Campos","year":"2003","journal-title":"Biochem J"},{"key":"B78-20250825","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 2","key":"B79-20250825","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.21037\/tau.2018.11.03","article-title":"Biomarkers and the role of mast cells as facilitators of inflammation and fibrosis in chronic kidney disease","volume":"8","author":"Owens","year":"2019","journal-title":"Transl Androl Urol"},{"key":"B80-20250825","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1535370216684040","article-title":"Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort","volume":"242","author":"Wolke","year":"2017","journal-title":"Exp Biol Med (Maywood)"},{"key":"B81-20250825","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14789450.2014.926224","article-title":"Urinary proteomics and molecular determinants of chronic kidney disease: Possible link to proteases","volume":"11","author":"Filip","year":"2014","journal-title":"Expert Rev Proteomics"},{"key":"B82-20250825","doi-asserted-by":"crossref","first-page":"F1351","DOI":"10.1152\/ajprenal.00037.2012","article-title":"Matrix metalloproteinases in kidney homeostasis and diseases","volume":"302","author":"Tan","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"B83-20250825","doi-asserted-by":"crossref","first-page":"e10378","DOI":"10.1002\/jbm4.10378","article-title":"FAM20C-mediated phosphorylation of MEPE and its acidic serine- and aspartate-rich motif","volume":"4","author":"Christensen","year":"2020","journal-title":"JBMR Plus"},{"key":"B84-20250825","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1126\/science.1217817","article-title":"Secreted kinase phosphorylates extracellular proteins that regulate biomineralization","volume":"336","author":"Tagliabracci","year":"2012","journal-title":"Science"},{"key":"B85-20250825","doi-asserted-by":"crossref","first-page":"e42988","DOI":"10.1371\/journal.pone.0042988","article-title":"The Raine syndrome protein FAM20C is a Golgi kinase that phosphorylates bio-mineralization proteins","volume":"7","author":"Ishikawa","year":"2012","journal-title":"PLoS One"},{"key":"B86-20250825","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coph.2015.03.006","article-title":"A unified model for bone-renal mineral and energy metabolism","volume":"22","author":"Rowe","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"B87-20250825","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"B88-20250825","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.2215\/CJN.02740311","article-title":"Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study","volume":"6","author":"Guti\u00e9rrez","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B89-20250825","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"B90-20250825","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"key":"B91-20250825","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1161\/01.CIR.92.11.3249","article-title":"Effect of lean body mass, fat mass, blood pressure, and sexual maturation on left ventricular mass in children and adolescents. Statistical, biological, and clinical significance","volume":"92","author":"Daniels","year":"1995","journal-title":"Circulation"},{"key":"B92-20250825","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1210\/jcem.82.8.4181","article-title":"Cardiovascular abnormalities in patients with X-linked hypophosphatemia","volume":"82","author":"Nehgme","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B93-20250825","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kint.2018.03.024","article-title":"FGF23 effects on the heart-levels, time, source, and context matter","volume":"94","author":"Faul","year":"2018","journal-title":"Kidney Int"},{"key":"B94-20250825","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","article-title":"Bone and mineral disorders in chronic kidney disease: Implications for cardiovascular health and ageing in the general population","volume":"6","author":"Covic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B95-20250825","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1210\/en.2018-00174","article-title":"Increased circulating FGF23 does not lead to cardiac hypertrophy in the male Hyp mouse model of XLH","volume":"159","author":"Liu","year":"2018","journal-title":"Endocrinology"},{"key":"B96-20250825","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3390\/biomedicines10071691","article-title":"Activation of RAAS signaling contributes to hypertension in aged Hyp mice","volume":"10","author":"Latic","year":"2022","journal-title":"Biomedicines"},{"key":"B97-20250825","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1681\/ASN.2008101106","article-title":"Dietary phosphorus acutely impairs endothelial function","volume":"20","author":"Shuto","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B98-20250825","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00003.2008","article-title":"Increased inorganic phosphate induces human endothelial cell apoptosis in vitro","volume":"294","author":"Di Marco","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"B99-20250825","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/hh2401.101070","article-title":"Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers","volume":"89","author":"Steitz","year":"2001","journal-title":"Circ Res"},{"key":"B100-20250825","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res"},{"key":"B101-20250825","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/ndt\/gfr609","article-title":"Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD","volume":"27","author":"Smith","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B102-20250825","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1681\/ASN.2009090944","article-title":"Fetuin-mineral complex reflects extraosseous calcification stress in CKD","volume":"21","author":"Hamano","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B103-20250825","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1097\/01.ASN.0000068404.57780.DD","article-title":"BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure","volume":"14","author":"Davies","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B104-20250825","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semnephrol.2009.01.008","article-title":"The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: The links between bone and the vasculature","volume":"29","author":"Hruska","year":"2009","journal-title":"Semin Nephrol"},{"key":"B105-20250825","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-2002-33256","article-title":"Up-regulation of liver glucose-6-phosphatase in x-linked hypophosphatemic mice","volume":"34","author":"Xie","year":"2002","journal-title":"Horm Metab Res"},{"key":"B106-20250825","first-page":"F357","article-title":"X-linked hypophosphatemic rickets and the murine Hyp homologue","volume":"268","author":"Hruska","year":"1995","journal-title":"Am J Physiol"},{"key":"B107-20250825","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1210\/endo.130.1.1309337","article-title":"Altered proximal tubule glucose metabolism in X-linked hypophosphatemic mice","volume":"130","author":"Capparelli","year":"1992","journal-title":"Endocrinology"},{"key":"B108-20250825","first-page":"633","article-title":"Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction","volume":"10","author":"Russo","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B109-20250825","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3892\/mmr.2017.6997","article-title":"Adipose differentiation-related protein knockdown inhibits vascular smooth muscle cell proliferation and migration and attenuates neointima formation","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Med Rep"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002782022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:01:44Z","timestamp":1786478504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002782022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0002782022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"2022-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}